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KEYWORDS	
	 Two	 metal	 complexes	 of	 Ti(IV)	 were	 synthesized	 with	 newly	 prepared	 biologically	 active
ligands.	These	ligands	and	their	functional	groups	were	carefully	designed	and	selected	from
well	known	anticancer	drugs.	The	ligands	were	prepared	by	the	condensation	of	a	mixture	of
sulfamethoxazole	 and	 the	 appropriate	 aldehyde	 namely,	 3,4‐dimethoxybenzaldehyde	 and
3,4,5‐trimethoxybenzaldehyde.	 The	 structure	 of	 the	 ligands	 and	 their	 complexes	 were
confirmed	 by	 spectroscopic	 data	 i.e.	 IR,	 1H	 NMR,	 electronic	 and	 elemental	 analysis.	 All
compounds	were	screened	for	their	in	vitro	anticancer	potential	using	HELA	and	PC3	cells.	All
compounds	 showed	 limited	 cytotoxicity	 and	 complete	 cleavage	 of	 calf	 thymus
deoxyribonucleic	acid	(CT‐DNA).	
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1.	Introduction	
	
Coordination	compounds	of	biologically	active	ligands	have	
received	much	attention	[1‐3].	Chelation	causes	drastic	change	
in	 the	 biological	 properties	 of	 the	 ligands	 and	 also	 the	metal	
moiety.	 A	 number	 of	 Schiff‐base	 complexes	 [4‐7]	 have	 been	
tested	for	biological	activities	and	showed	antibacterial	[8‐11],	
antifungal	 [10‐12],	 anticancer	 [13‐14]	 and	 herbicidal	 [15]	
activities.	It	is	known	that	the	existence	of	metal	ions	bonded	to	
biologically	active	compounds	may	enhance	their	activities	[16‐
18].	 Following	 the	 discovery	 of	 cis‐platin	 and	 its	 anticancer	
activity,	 there	has	been	a	growing	 interest	 in	 investigations	of	
other	platinum‐based	compounds	[19]	as	well	as	non‐platinum	
systems,	 and	 evaluating	 their	 potential	 value	 as	 anticancer	
reagents	[20‐23].	
Among	other	metals	that	have	been	studied,	two	families	of	
titanium	complexes,	titanocene	dichloride	and	derivatives,	and	
budotitane	and	analogs,	showed	interesting	activities	towards	a	
number	 of	 tumor	 cell	 types,	 including	 those	 resistant	 to	 cis‐
platin,	and	with	reduced	toxicity	[24‐30].	
A	 variety	 of	 possible	 Schiff	 base	 metal	 complexes	 with	 a	
wide	 choice	 of	 ligands,	 and	 coordination environments,	 have	
prompted	 us	 to	 undertake	 research	 in	 this	 area	 [31‐32].	
Metallocene	 dichlorides	 (Cp2MCl2)	with	M	=	Ti,	 V,	Nb	 and	Mo	
show	remarkable	antitumor	activity	[33‐34].	We	are	interested	
in	 studying	 titanium	 complexes	 in	 more	 detail,	 and	
investigating	additional	non‐Cp‐based	systems.		
In	 continuation	 of	 our	 previous	 studies	 [35]	 in	 this	work,	
Schiff	 base	 ligands	 were	 prepared	 by	 condensation	 of	 an	
equimolar	 mixture	 of	 sulfamethoxazole	 and	 the	 aldehyde	
(3,4,5‐trimethoxybenzaldehyde	 or	 3,4‐dimethoxybenzalde‐
hyde).	The	 ligands	were	 reacted	with	 titanium(IV)	 chloride	 to	
get	Schiff‐base	complexes.	Characterization,	electronic	proper‐
ties,	DNA	cleavage	and	anticancer	effects	were	reported.	
	
2.	Experimental	
	
2.1.	Chemicals	
	
Sulfamethoxazole	was	purchased	from	Virchow	Drugs	Ltd.,	
India.	 Titanium	 tetrachloride,	 3,4,5‐trimethoxybenzaldehyde	
and	 3,4‐dimethoxybenzaldehyde	 were	 obtained	 commercially	
from	Aldrich	Chemicals.	The	solvents:	dry	absolute	ethanol	and	
diethyl	ether	were	reagent	grade	and	were	used	as	received. 
	
2.2.	Instrumentation	
	
The	 melting	 points	 were	 measured	 on	 an	 electrothermal	
melting	point	apparatus	and	were	not	corrected.		
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Scheme	1
	
	
Fourier‐transform	 infrared	 spectra	 were	 recorded	 using	
the	 KBr	 disc	 technique	 on	 a	 JASCO	 410	 FTIR	
spectrophotometer.	 Elemental	 (CHN)	 analysis	 was	 performed	
using	 an	 Exeter	 CE‐440	 elemental	 analyzer.	 UV‐visible	
absorption	spectra	were	measured	in	DMF	using	a	Pye‐Unicam	
8800a	 UV‐visible	 automatic	 scanning	 spectrophotometer.	
Molar	 conductivity	was	measured	 on	 a	 systronic	 conductivity	
bridge	 with	 a	 dip‐type	 cell,	 using	 1×10‐3	 M	 solution	 of	
complexes	 in	 DMF.	 1H	 NMR	 spectra	 of	 the	 ligands	 and	 their	
complexes	 were	 recorded	 on	 a	 Varian	 Gemini‐200	
spectrometer	 using	 DMSO‐d6	 as	 solvent	 and	 TMS	 as	 internal	
reference.	 Anticancer	 activity	 was	 evaluated	 at	 the	
International	 Center	 for	 Chemical	 Sciences	 and	 Dr.	 Panjwani	
Center	for	Molecular	Medicine	and	Drug	Research,	University	of	
Karachi,	Pakistan.	
	
2.3.	Synthesis	of	Schiff	base	ligands	
	
Schiff	 base	 compounds	were	prepared	by	condensation	of	
an	equimolar	mixture	 (0.01	mol)	of	 sulfamethoxazole	 and	 the	
aldehyde	 (0.01	 mol)	 3,4,5‐trimethoxybenzaldehyde	 or	 (0.01	
mol)	 3,4‐dimethoxybenzaldehyde,	 respectively,	 in	 ethanol	 (25	
mL).	 The	 mixture	 was	 refluxed	 for	 24	 hours	 under	 nitrogen	
atmosphere.	Schiff	base	compounds	were	isolated	and	purified	
by	 diethyl	 ether	 after	 reduction	 of	 solvent	 volume	 by	
evaporation	in	a	rotary	evaporator	(Scheme	1	and	2).		
4‐(3,4‐Dimethoxybenzylideneamino)‐N‐(5‐methylisoxazol‐3‐
yl)benzene	 sulfonamide	 (1):	 Color:	 Orange.	 Yield:	 92%.	 M.p.:	
204‐205	°C.	FT‐IR	(KBr,	,	cm‐1):	3432	(NH),	1654	(C=N),	1619	
(C=N),	1576	(C=C).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	10.99	
(s,	 1H,	 D2O	 exchangeable	 NH),	 9.79	 (s,	 1H,	 CH,	 azomethine),	
6.59‐7.47	 (m,	 7H,	 Ar‐H),	 6.06	 (s,	 1H,	 isoxazole),	 3.72	 (s,	 3H,	
OCH3),	 3.84	 (s,	 3H,	OCH3),	 2.29	 (s,	 3H,	 CH3	methyl	 isoxazole).	
Anal.	calcd.	for	C19H19O5N3S:	C,	56.85;	H,	4.77;	N,	10.47.	Found:	
C,	56.08;	H,	3.90;	N,	9.24%.	UV/Vis	(DMF,	λmax,	nm,):	215,	292,	
343.	
N‐(5‐Methylisoxazol‐3‐yl)‐4‐(3,4,5‐trimethoxybenzylidene	
amino)benzene	sulfonamide	(3):	Color:	Yellow.	Yield:	75%.	M.p.:	
220‐223	°C.	FT‐IR	(KBr,	,	cm‐1):	3430	(NH),	1656	(C=N),	1623	
(C=N	ring),	1580	(C=C).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	
10.95	 (S,	 1H,	 D2O	 exchangeable	 NH),	 9.88	 (s,	 1H,	 CH,	
azomethine),	 6.60‐7.49	 (m,	 6H,	 Ar‐H),	 6.08	 (s,	 1H,	 isoxazole),	
3.74	(s,	3H,	OCH3),	3.85	(s,	6H,	OCH3),	2.28	(s,	3H,	CH3	methyl	
isoxazole).	 Anal.	 calcd.	 for	 C20H21O6N3S:	 C,	 55.67;	 H,	 4.91;	 N,	
9.74.	 Found:	 C,	 54.20;	 H,	 3.77;	 N,	 9.10%.	 UV/Vis	 (DMF,	 λmax,	
nm):	213,	292,	344.	
	
2.4.	Synthesis	of	Schiff	base	complexes	
	
Schiff	base	compounds	(0.02	mol)	were	reacted	as	 ligands	
with	(0.01	mol)	 titanium	tetrachloride	 in	refluxing	ethanol	 for	
24	 hrs	 under	 nitrogen	 to	 give	 Schiff	 dibase	 complexes.	 The	
precipitates	were	crystallized	from	ethanol	(Scheme	1	and	2).	
4‐(3,4‐Dimethoxybenzylideneamino)‐N‐(5‐methylisoxazol‐3‐
yl)benzene	 sulfonamide	 titanium	 complex	 (2):	 Color:	 Reddish	
brown.	Yield:	50%.	M.p.:	232‐233	°C.	FT‐IR	(KBr,	,	cm‐1):	3432	
(NH),	1652	(C=N),	1622	(C=N	ring),	1594	(C=C).	1H	NMR	(300	
MHz,	DMSO‐d6,	 δ,	 ppm):	 10.94	 (s,	 2H,	 D2O	 exchangeable	NH),	
9.84	(s,	2H,	CH,	azomethine),	6.57‐7.58	(m,	14H,	Ar‐H),	6.08	(s,	
2H,	 isoxazole),	 3.82	 (s,	 6H,	OCH3),	 3.86	 (s,	 6H,	OCH3),	 2.27	 (s,	
6H,	CH3	methyl	isoxazole).	Anal.	calcd.	for	C38H38O10N6S2TiCl4:	C,	
45.98;	 H,	 3.86;	 N,	 8.47.	 Found:	 C,	 45.20;	 H,	 3.90;	 N,	 8.20%.	
UV/Vis	 (DMF,	 λmax,	 nm):	 215,	 281,	 363,	 414.	 Λm	 (S.cm2.mol‐1):	
42.	
N‐(5‐Nethylisoxazol‐3‐yl)‐4‐(3,4,5‐trimethoxybenzylidene	
amino)benzene	 sulfonamide	 titanium	 complex	 (4):	Color:	 Dark	
yellow.	Yield:	32%.	M.p.:	169‐171	°C.	FT‐IR	(KBr,	,	cm‐1):	3438	
(NH),	1650	(C=N),	1623	(C=N	ring),	1583	(C=C).	1H	NMR	(300	
MHz,	DMSO‐d6,	 δ,	 ppm):	 11.05	 (s,	 2H,	 D2O	 exchangeable	NH),	
9.83	(s,	2H,	CH,	azomethine),	6.80‐7.59	(m,	12H,	Ar‐H),	6.09	(s,	
2H,	 isoxazole),	3.82	(s,	6H,	OCH3),	3.87	(s,	12H,	OCH3),	2.27	(s,	
6H,	CH3	methyl	isoxazole).	Anal.	calcd.	for	C40H42O12N6S2TiCl4:	C,	
45.64;	 H,	 4.02;	 N,	 7.98.	 Found:	 C,	 45.86;	 H,	 3.40;	 N,	 7.78%.	
UV/Vis	(DMF,	λmax,	nm):	214,	268,	400.	Λm	(S.cm2.mol‐1):	93.6.	
	
2.5.	Gel	electrophoresis	
	
The	 DNA	 cleavage	 experiment	 was	 conducted	 using	 CT‐
DNA	by	gel	electrophoresis	with	the	ligand	and	metal	complex	
in	the	absence	and	presence	of	H2O2	as	an	oxidant.		
	
	
412	 El‐Shekeil	et	al.	/	European	Journal	of	Chemistry	5	(3)	(2014)	410‐414	
	
	
	
Scheme	2	
	
	
The	reaction	mixture	was	incubated	before	electrophoresis	
experiment	 at	 37	 °C	 for	 2	h	 as	 follows:	 Calf	 thymus	DNA,	 CT‐
DNA	30	μM,	50	μM,	each	complex	and	500	μM	H2O2	 in	50	mM	
Tris‐HCl	 buffer	 (pH	=	7.1).	 The	 samples	were	 electrophoresed	
for	2	h	at	50	V	on	1%	agarose	gel	using	 tris‐acetic	acid‐EDTA	
buffer	 at	 pH	 =	 8.3.	 After	 electrophoresis,	 the	 gel	 was	 stained	
using	3	μL	ethidium	bromide	(EB)	and	photographed	under	UV	
light	using	a	digital	camera.	 
	
2.6.	Cytotoxicity		
	
The	 cytotoxic	 activity	 of	 the	 compounds	was	 evaluated	 in	
96‐well	 flat‐bottomed	microplates	by	using	 the	 standard	MTT	
(3‐[4,5‐dimethylthiazole‐2‐yl]‐2,5‐diphenyl‐tetrazolium	
bromide)	 colorimetric	 assay	 [36].	 For	 this	purpose,	PC‐3	 cells	
(Prostate	 cancer)	 and	 Hela	 cells	 were	 cultured	 in	 Dulbecco’s	
Modified	 Eagle’s	 Medium,	 and	 Minimal	 Essential	 Medium	
(MEM),	 supplemented	 with	 5%	 of	 fetal	 bovine	 serum	 (FBS),	
100	IU/mL	of	penicillin	and	100	µg/mL	of	streptomycin	 in	25	
cm3	flask,	and	kept	in	5%	CO2	incubator	at	37	°C.	Exponentially	
growing	 cells	 were	 harvested,	 counted	 with	 haemocytometer	
and	 diluted	 with	 a	 particular	 medium.	 Cell	 culture	 with	 the	
concentration	of	1×105	cells/mL	was	prepared	and	introduced	
(100	 µL/well)	 into	 96‐well	 plates.	 After	 overnight	 incubation,	
medium	was	removed	and	200	µL	of	fresh	medium	was	added	
with	 different	 concentrations	 of	 compounds	 (1,	 10	 and	 100	
µM).	After	48	h,	50	µL	MTT	(2	mg/mL)	was	added	to	each	well	
and	 incubated	 further	 for	 4	 hours.	 Subsequently,	 100	 µL	 of	
DMSO	was	added	to	each	well.	The	extent	of	MTT	reduction	to	
formazan	 within	 cells	 was	 calculated	 by	 measuring	 the	
absorbance	at	570	nm,	using	a	micro	plate	reader	(Spectra	Max	
plus,	 Molecular	 Devices,	 CA,	 USA).	 The	 cytotoxicity	 was	
recorded	 as	 concentration	 causing	 50%	 growth	 inhibition	
(IC50).	
	
3.	Result	and	discussion	
	
3.1.	Synthesis	and	characterization	
	
Schiff	 base	 ligand	 was	 prepared	 by	 reaction	 of	
sulfamethoxazole	 with	 3,4‐dimethoxybenzaldehyde	 or	 3,4,5‐
trimethoxybenzaldehyde	in	refluxing	solvent.	Schiff	base	ligand	
(0.02	mole)	was	 reacted	with	 TiCl4	 (0.01	mole)	 to	 give	 Schiff	
dibase	complexes	(Scheme	1	and	2).		
	
3.2.	Conductance	measurements	
	
All	 Ti	 complexes	 (2	 and	 4)	 are	 electrolytes	 as	 shown	 by	
their	molar	conductivity	(Λm)	measurements	in	DMF,	which	are	
42	and	93.6	S.cm2mol‐1,	respectively.		
	
3.3.	IR	spectra		
	
The	 assigned	 absorption	 bands	 are	 consistent	 with	 the	
suggested	 structures.	 The	 aromatic	 C=C	 vibrations	 were	
observed	in	the	range	1576‐1596	cm‐1;	the	azomethane	band	is	
seen	at	1650‐1656	cm‐1;	NH	single	bond	of	sulfamethoxazaole	
at	 3430‐3438	 cm‐1	 [37]	 and	 C=N	 oxazole	 ring	 at	 1619‐1623				
cm‐1	[38].	
	
3.4.	1H	NMR	study	of	Schiff	base	
	
1H	NMR	spectrum	of	 the	Schiff	base	 (1),	 4‐(3,4‐dimethoxy	
benzylideneamino)‐N‐(5‐methylisoxazol‐3‐yl)benzene	 sulfon‐
amide,	showed	NH	proton	of	sulfonamide	at	10.99	ppm	(s,	1H,	
D2O	exchangeable),	CH3	of	methyl	isoxazole	at	2.29	ppm	(s,	3H),	
azomethine	 proton	 noted	 at	 9.79	 ppm	 (m,	 1H).	 The	 multiple	
signals	around	6.59‐7.47	ppm	(m,	7H)	are	ascribed	to	aromatic	
protons.	 The	 signal	 observed	 at	 6.06	 ppm	 (s,	 1H)	 is	 due	 to	
isoxazole	proton.	OCH3	protons	showed	up	at	3.72	ppm	(s,	3H)	
and	at	3.84	ppm	(s,	3H).	
1H	 NMR	 spectrum	 of	 the	 Schiff	 base	 (3),	 N‐(5‐methyl	
isoxazol‐3‐yl)‐4‐(3,4,5‐trimethoxybenzylideneamino)	 benzene	
sulfonamide,	 showed	NH	proton	of	 sulfonamide	at	10.95	ppm	
(s,	1H,	D2O	exchangeable),	CH3	of	methyl	isoxazole	at	2.28	ppm	
(s,	3H)	and	azomethine	proton	noted	at	9.88	ppm	(s,	1H).	The	
multiple	signals	around	6.60‐7.49	ppm	(m,	6H)	are	ascribed	to	
aromatic	protons.	Signal	observed	at	6.08	ppm	(s,	1H)	is	due	to	
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isoxazole	proton.	OCH3	protons	were	noted	at	3.74	ppm	(s,	3H)	
and	at	3.85	ppm	(s,	6H).	
	
	3.5.	1H	NMR	study	of	the	complexes	
	
In	 the	 1H	 NMR	 spectra	 of	 the	 complexes	 (2	 and	 4)	 an	
electron	density	shift	from	the	ligand	to	the	metal	complex	was	
observed.	The	signals	of	azomethine	protons	appeared	at	9.84	
and	 9.83	 ppm	 in	 the	 compound	 2	 and	 4,	 respectively,	 as	
compared	 to	 9.79	 ppm	 and	 9.88	 ppm	 in	 the	 Schiff	 base,	
confirming	coordination	through	the	azomethine	nitrogen	atom	
of	the	ligand	[39].	
	
3.6.	Electronic	spectra	
	
The	main	electronic	absorptions	are	shown	in	Figure	1.	UV‐
Vis	spectra	of	the	 ligands	and	their	complexes	were	measured	
in	 the	 range	200‐800	nm.	The	 lower	wavelength	 in	 the	 range	
200‐400	 nm	 is	 specific	 for	 the	 electronic	 intra‐ligand	
transitions.	 The	 spectra	 of	 complexes	 generally	 show	 the	
characteristic	band	of	the	free	ligands	with	some	changes	both	
in	wavelengths	(λmax)	and	intensity,	together	with	appearances	
of	new	bands	at	longer	wavelengths.	The	spectra	of	the	ligands	
and	 their	 complexes	 exhibit	 bands	 in	 the	 regions	 of	 213‐215,	
268‐292	 and	 343‐414	 nm,	 which	 may	 be	 attributed	 to	 the	
transitions	of	σ	→	σ*,	π	→	π*	and	n	→	π*,	respectively.		
	
	
	
Figure	1.	UV‐Vis	spectra	of	the	two	ligands	and	their	metal	complexes.	
	
	
3.7.	DNA	cleavage	studies	
	
The	cleavage	efficiency	of	the	complexes	compared	to	that	
of	 control	 is	 due	 to	 their	 efficient	 DNA‐binding	 ability.	 The	
metal	 complexes	were	 able	 to	 convert	 super	 coiled	 DNA	 into	
open	 circular	 DNA.	 The	 proposed	 general	 oxidative	
mechanisms	 and	 account	 of	 DNA	 cleavage	 is	 by	 hydroxyl	
radicals	 via	 abstraction	 of	 a	 hydrogen	 atom	 from	 sugar	 units	
that	 predict	 the	 release	 of	 specific	 residues	 arising	 from	
transformed	sugars,	depending	on	the	position	from	which	the	
hydrogen	atom	is	removed	[40].	Free	radical	scavengers	inhibit	
cleavage.	 This	 implies	 that	 hydroxyl	 radical	 or	 peroxy	
derivatives	 mediate	 the	 cleavage	 reaction.	 The	 reaction	 is	
modulated	 by	 metal	 complexes	 bound	 hydroxyl	 radical	 or	 a	
peroxo	species	generated	from	the	co‐reactant	H2O2.	
In	 the	 present	 study,	 CT‐DNA	 gel	 electrophoresis	
experiment	 was	 conducted	 at	 35	 °C	 using	 our	 synthesized	
complexes	in	the	presence	of	H2O2	as	an	oxidant.	As	can	be	seen	
from	 the	 results	 illustrated	 in	 Figure	 2	 and	 3,	 at	 very	 low	
concentrations,	 all	 ligands	 and	 their	 complexes	 exhibited	
nuclease	activity	in	the	presence	of	H2O2.	Control‐1	experiment,	
using	DNA	alone	(line	1)	did	not	show	any	significant	cleavage	
of	 CT‐DNA	 even	 on	 a	 longer	 exposure	 time.	 Control‐2,	 using	
DNA+H2O2	(line	2)	did	not	show	any	significant	cleavage	of	CT‐
DNA.	 From	 the	 observed	 results,	 it	 can	 be	 concluded	 that	 all	
ligands	 (lines	 3	 and	 5)	 and	 their	 complexes	 (lines	 4	 and	 6)	
showed	complete	cleavage	of	CT‐DNA.		
	
	
Figure	 2.	 DNA	 with	 hydrogen	 peroxide	 and	 chemical	 compounds:	 1‐DNA	
alone;	 2‐DNA	 +	 H2O2;	 3‐DNA	 +	 H2O2	 +	 Compound	 1;	 4‐DNA	 +	 H2O2	 +	
Compound	2;	5‐DNA	+	H2O2	+	Compound	3;	6‐DNA	+	H2O2	+	Compound	4.	
	
	
	
	
Figure	3.	 DNA	without	 hydrogen	 peroxide:	 1‐DNA	 alone;	 2‐DNA	 +	 solvent	
(DMSO);	3‐DNA	+	Compound	1;	4‐DNA+	Compound	2;	5‐DNA	+	Compound	3;	
6‐DNA	+	Compound	4.	
	
	
3.8.	Anti‐cancer	activity		
	
The	 results	of	 the	 in	vitro	 anticancer	 activity	of	 the	 tested	
compounds	 1‐4	 were	 evaluated	 for	 cytotoxicity	 against	 PC3	
cells	(Prostate	cancer)	and	Hela	cells	of	humans	in	comparison	
with	 doxorubicin	 as	 a	 positive	 control.	 All	 the	 tested	
compounds	 showed	 a	 limited	 cytotoxic	 activity.	 Table	 1	
represents	the	cytotoxic	activity	of	the	tested	compounds.	
	
Table	1.	Cytotoxic	activity	against	Hela	cells	and	PC3	cells.	
Compound	 PC3	 Hela	
IC50 ±	SD	(μM)	 IC50	±	SD	(μM)
1	 35.67±1.7	 37.66±0.2	
2	 32.6±0.5	 36.75±1.0	
3	 50.76±0.2	 54.98±1.1	
4 >100 >100	
Doxorubicin	(as	control) 0.912±0.120	 3.10±0.2
	
	
4.	Conclusion	
	
The	present	work	describes	the	synthesis,	characterization	
and	 in	 vitro	 anticancer	 evaluation	 of	 two	 sulfonamide	
derivatives	 and	 their	 complexes.	 With	 regard	 to	 anticancer	
activity	we	 expected	 the	 titanium	 complexes	 to	 give	 excellent	
cytotoxic	 activity,	 however	 all	 tested	 compounds	 showed	
limited	cytotoxic	activity	and	complete	cleavage	of	CT‐DNA.		
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